Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab immunotherapy for obsessive-compulsive disorder (open pilot study)
2018-004619-28Phase 2Completed
- Sponsor
- Region Örebro län
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in refractory obsessive-compulsive disorder (TR-OCD), sponsored by Region Örebro län. Primary endpoint: Change in Y-BOCS score. Started Dec 2018; status: completed.
02
Drugs
rituximab
03
Conditions
refractory obsessive-compulsive disorder (TR-OCD)
Beyond the preview
Go deeper on 2018-004619-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004619-28.